Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine whether fixed-doses of an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Auspex Pharmaceuticals, Inc.
NCT07365462 · Tardive Dyskinesia
NCT07173920 · Tardive Dyskinesia, Repetitive Transcranial Magnetic Stimulation
NCT06997198 · Tardive Dyskinesia, Intellectual Disability, and more
NCT05859698 · Schizophrenia, Schizoaffective Disorder, and more
NCT06474650 · Huntington Disease, Tardive Dyskinesia
Teva Investigational Site 145
Tuscaloosa, Alabama
Teva Investigational Site 107
Anaheim, California
Teva Investigational Site 108
Anaheim, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions